Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report

White House estimates Trump's drug pricing agreements could save $529 billion in next decade, but analysis draws scrutiny.

Eli Lilly To Invest Additional $4.5B Across Two Indiana Facilities

Eli Lilly and Company (NYSE:LLY) today announced an additional $4.5 billion investment across two of its three Lebanon sites—bringing the company's total Indiana capital expansion commitments since 2020 to more than $21

Robert F. Kennedy Jr. Wants To Take 'Clear And Decisive Action' On Psychiatric Drugs Amid 'Deprescribing' Push: Big Pharma Should Pay Attention

Robert F. Kennedy Jr. unveiled a federal initiative to curb the overuse of psychiatric medications, emphasizing deprescribing and a shift toward preventive, patient-centered mental health care.

Live On CNBC, Bill Baruch Announces Bought Eli Lilly

Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence

Eli Lilly shares rise as Omvoh shows 4-year disease clearance in ulcerative colitis, with consistent safety and strong Crohn's data.

Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $1400

Barclays analyst Emily Field maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1350 to $1400.

Guggenheim Reiterates Buy on Eli Lilly, Maintains $1183 Price Target

Guggenheim analyst Seamus Fernandez reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $1183 price target.

Eli Lilly Announces New Long-Term Data Show That Patients With Moderately To Severely Active Ulcerative Colitis Treated With Omvoh Achieved Durable Disease Clearance Through Four Years Of Con

 In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years. These results will be presented at Digestive Disease Week®

Wolfe Research Reiterates Outperform on Eli Lilly, Maintains $1325 Price Target

Wolfe Research analyst Alexandria Hammond reiterates Eli Lilly (NYSE:LLY) with a Outperform and maintains $1325 price target.

GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is...'

Deloitte says pharma momentum drives investment interest, but rising competition is limiting growth opportunities in sector.